Montgomery Street

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, April 16, 2024
Sale, Prospectus, Capital market, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, RBC, Suite, Security (finance), Nicollet Mall, Form, Exercise, S-3, Attention, Therapy, Telephone, SAN, Needham & Company

SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.

Key Points: 
  • SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock.
  • The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $188.6 million.
  • J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated acted as joint book-running managers for the offering.
  • The public offering was made pursuant to a shelf registration statement on Form S-3 (File No.

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Retrieved on: 
Friday, April 12, 2024
Sale, Prospectus, Capital market, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, RBC, Suite, Security (finance), Research, Nicollet Mall, Form, Attention, Therapy, Telephone, SAN, Needham & Company

SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.

Key Points: 
  • SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share.
  • The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million.
  • Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering.
  • The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions.

Nurix Therapeutics Announces Proposed Public Offering

Retrieved on: 
Thursday, April 11, 2024
Sale, Prospectus, Cancer, RBC Capital Markets, Broadridge Financial Solutions, Montgomery Street, Suite, Security (finance), Research, Nicollet Mall, Form, Patient, Inflammation, Attention, Therapy, Telephone, SAN, Needham & Company

In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.

Key Points: 
  • In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the proposed offering.
  • Needham & Company, LLC and RBC Capital Markets, LLC are acting as lead managers for the proposed offering.

Contineum Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, April 5, 2024
Montgomery Street, Goldman Sachs, Vesey Street, Telephone, Inflammation, SAN, Sale, Attention, Security (finance), Prospectus, Morgan Stanley, Suite, Therapy, Varick Street, Equity capital markets, RBC Capital Markets

All of the shares are being offered by Contineum.

Key Points: 
  • All of the shares are being offered by Contineum.
  • The gross proceeds to Contineum from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Contineum, are expected to be $110.0 million.
  • In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,031,250 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Morgan Stanley, Stifel, and RBC Capital Markets are acting as joint book-running managers for the offering.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
Monday, March 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Retrieved on: 
Tuesday, March 19, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.

Key Points: 
  • The size of the offering was increased by $100 million subsequent to the initial announcement of the offering.
  • The gross proceeds to Madrigal from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $600 million.
  • Madrigal has granted the underwriters of the offering a 30-day option to purchase up to an additional 346,153 shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.

Madrigal Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Monday, March 18, 2024
Montgomery Street, Fatty liver disease, UBS, ECM, Madison Avenue, Goldman Sachs, Form, Telephone, Citizenship, Research, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Jefferies, NASH, Therapy, Nicollet Mall, Equity capital markets, Jefferies Group, ATTN:, Evercore

Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Madrigal also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the shares in the proposed offering are to be sold by Madrigal.
  • Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Evercore ISI, Piper Sandler, UBS Investment Bank and Citizens JMP are acting as joint bookrunning managers of the proposed offering.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

Retrieved on: 
Tuesday, March 12, 2024
BofA Securities, Montgomery Street, Exercise, Madison Avenue, Atopic dermatitis, Goldman Sachs, Telephone, SAN, Chronic obstructive pulmonary disease, Sale, Attention, Security (finance), Lexington Avenue, Asthma, Suite, Apsis, Prospectus, Therapy, Jefferies, Jefferies Group

The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.

Key Points: 
  • The aggregate gross proceeds to Apogee from the offering were approximately $483.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.
  • All of the shares were offered by Apogee.
  • Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel acted as joint book-running managers for the offering.
  • Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on March 7, 2024.

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Tuesday, March 19, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Montgomery Street, Form, Telephone, Corporation, Sale, Attention, Syndrome, Security (finance), Lexington Avenue, Suite, Form S-3, Prospectus, OrbiMed, Geron Corporation

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock.
  • All of the securities in the offering are to be sold by Geron.
  • The offering is expected to close on or about March 21, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million.

Ichor Holdings, Ltd. Announces Pricing of $125 Million Public Offering

Retrieved on: 
Thursday, March 14, 2024
Semiconductor, Engineering, Chemicals, Plastics, Technology, Manufacturing, Hardware, Montgomery Street, Needham & Company, Form, Telephone, Sale, Public expenditure, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, File, ICHR

In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its ordinary shares at the public offering price, less underwriting commissions.

Key Points: 
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its ordinary shares at the public offering price, less underwriting commissions.
  • The offering is expected to close on March 18, 2024, subject to the satisfaction of customary closing conditions.
  • TD Cowen and Stifel are acting as joint book-running managers and representatives of the underwriters for the offering.
  • The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.